633 related articles for article (PubMed ID: 32482373)
1. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
2. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
[TBL] [Abstract][Full Text] [Related]
3. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
[TBL] [Abstract][Full Text] [Related]
4. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
5. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
7. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
8. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
9. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
10. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
12. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.
Zhang S; Li L; Shen A; Chen Y; Qi Z
Clin Drug Investig; 2020 Jun; 40(6):511-518. PubMed ID: 32337664
[TBL] [Abstract][Full Text] [Related]
13. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Luo W; Li YX; Jiang LJ; Chen Q; Wang T; Ye DW
Trends Pharmacol Sci; 2020 Aug; 41(8):531-543. PubMed ID: 32580895
[TBL] [Abstract][Full Text] [Related]
14. Preemptive interleukin-6 blockade in patients with COVID-19.
Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
[TBL] [Abstract][Full Text] [Related]
15. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
[TBL] [Abstract][Full Text] [Related]
19. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
[TBL] [Abstract][Full Text] [Related]
20. IL-6: Relevance for immunopathology of SARS-CoV-2.
Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
